Treatment of patients with recurrent/refractory aggressive non-Hodgkin's lymphoma: effectiveness and safety of pixantrone
2016
Abstract
Treatment options for recurrent/refractory aggressive non-Hodgkin's lymphoma (NHL) are limited. Rituximab combined with anthracycline based regimens remain the mainstay of therapy.
However, repeated administration of anthracyclines is associated with substantial risk of cardiotoxicity. Pixantrone is anthracycline-like cytostatic with preserved antitumor activity and decreased cardiotoxicity with proven efficacy in the treatment of NHL.
On the basis of results from an international randomized PIX 301 trial, pixantrone monotherapy was approved by the European Medicines Agency (EMA) for the treatment of adults with multiply relapsed or refractory aggressive B-NHL. pixantrone - diffuse large B-cell lymphoma - cardiotoxicity - anthracyclines.